Shri Nandamuri Balakrishna inaugurated the prestigious ISDE India Edition 2026—an international conference on esophageal cancer—at The Westin Hyderabad, Madhapur. Notably, India is hosting this conference for the first time, marking a significant milestone in the country’s growing influence in cancer research and clinical excellence.
The two-day event, scheduled for April 10–11, is jointly hosted by the International Society for Diseases of the Esophagus (ISDE) and Basavatarakam Indo-American Cancer Hospital & Research Institute (BIACH & RI). Moreover, the conference coincides with the Silver Jubilee celebrations of BIACH & RI, highlighting 25 years of dedicated cancer care.
Global Participation and Knowledge Exchange
The conference has brought together over 150 oncologists from across the world, including experts from Canada, Singapore, Japan, Australia, and the United States. Alongside them, leading Indian clinicians are actively contributing to discussions, thereby fostering a rich exchange of global and local expertise.
A Landmark Moment for India and BIACH & RI
Speaking at the inauguration, Shri Nandamuri Balakrishna described the occasion as historic. He emphasized that hosting the first Indian edition of ISDE, alongside celebrating the institution’s Silver Jubilee, represents a powerful convergence of two milestones.
He highlighted that for 25 years, BIACH & RI has remained committed to making world-class cancer treatment accessible to all. Furthermore, he noted that the institution integrates research with clinical practice, ensuring that evidence-based care provides patients with the best possible outcomes. He added that the hospital continues to balance innovation, training, and compassionate service as a non-profit organization.
Conference as a Catalyst for Innovation
Balakrishna further stated that the conference would go beyond presentations and serve as a platform for transformative ideas and collaborations. He stressed that India now plays a pivotal role in global oncology, driven by its vast clinical experience, skilled professionals, and strong research capabilities.
As per press release, the event is expected to spark innovations, challenge conventional approaches, and foster collaborations that will shape the future of esophageal cancer treatment.
Understanding the Burden of Esophageal Cancer
Esophageal cancer remains an aggressive and often underdiagnosed disease. In India, the burden is particularly high due to risk factors such as tobacco use, alcohol consumption, gastroesophageal reflux disease (GERD), poor diet, and, in some regions, consumption of very hot beverages and malnutrition.
The disease shows rising incidence in states like Andhra Pradesh and Telangana, with higher prevalence reported in the North-East and Kashmir. Treatment approaches include surgery, chemotherapy, radiotherapy, and advanced targeted or immunotherapies, supported by innovations in diagnostics and minimally invasive techniques.
Vision for the Future of Cancer Care
Smt Nara Brahmani emphasized that the hospital was founded on a compassionate vision inspired by N.T. Rama Rao—to make quality cancer care accessible to everyone, regardless of socio-economic background. She noted that this vision has evolved into a mission combining clinical excellence with empathy, research with responsibility, and innovation with inclusivity.
Looking ahead, she stressed that India stands at a defining moment in oncology, with the potential to lead through its clinical volume, talent, and willingness to learn from diverse patient experiences.
Leadership and Institutional Excellence
Dr. T. Subramanyeswara Rao described the conference as a defining step in strengthening India’s global position in esophageal cancer care. He emphasized the importance of collaborative learning to address regional variations in disease treatment.
Dr. C.S. Pramesh highlighted the role of strong leadership in shaping institutions like BIACH & RI. He noted that the hospital’s continued success reflects visionary guidance and a well-built, self-sustaining team.
Shri JSR Prasad added that hosting ISDE in India reflects decades of clinical excellence and positions the country as a global leader in oncology. He reiterated the institution’s commitment to balancing excellence with equitable access to care.
Focus on Cutting-Edge Advancements
The conference will spotlight several advanced techniques and innovations, including:
- Minimally invasive and robotic esophagectomy
- Endoscopic Submucosal Dissection (ESD) for organ preservation
- Multimodal treatment approaches
- Translational research for targeted therapies
These advancements aim to improve precision in treatment and enhance patient outcomes.
Distinguished Global Faculty
The event features an eminent international faculty, including Prof. Lorenzo Ferri (Canada), Dr. Ken Kato and Dr. Hiroyuki Daiko (Japan), Dr. Edward Cheong (Singapore), Dr. Cuong Duong (Australia), and Dr. Steven Lin (USA). Prominent Indian experts, including Dr. T. Subramanyeswara Rao and Dr. C.S. Pramesh, are also contributing valuable insights tailored to the Indian context.
Strengthening Global Collaboration
In conclusion, ISDE India Edition 2026 stands as a landmark event that reinforces India’s role in the global fight against esophageal cancer. Through collaboration, innovation, and shared expertise, the conference aims to advance clinical excellence and improve patient outcomes worldwide.